Dr Dorla Mirejovsky joins Irvine Pharmaceutical Services
This article was originally published in Scrip
Dr Dorla Mirejovsky joins Irvine Pharmaceutical Service, a contract development and manufacturing organisation, as director of formulation development. Dr Mirejovsky was most recently in charge of the development and manufacture of several proprietary drug candidates at Spectrum Pharmaceuticals. She has over 25 years' experience in the pharma industry.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.